Dupilumab is approved for moderate-to-severe atopic dermatitis. Its mechanism of action is:
- A Monoclonal antibody blocking IL-4Rα (shared receptor subunit for IL-4 and IL-13 signalling) ✓
- B Anti-TNFα monoclonal antibody
- C Anti-IL-17A monoclonal antibody
- D Inhibitor of JAK1/JAK3
Correct answer: A. Monoclonal antibody blocking IL-4Rα (shared receptor subunit for IL-4 and IL-13 signalling)
Explanation
Dupilumab is a fully human monoclonal antibody that targets the IL-4 receptor alpha (IL-4Rα) subunit, which is shared by the receptor complexes for both IL-4 and IL-13. By blocking this subunit, dupilumab simultaneously inhibits both IL-4 and IL-13 signalling—the dominant Th2 cytokines driving type 2 inflammation in atopic dermatitis. It is also approved for asthma, chronic rhinosinusitis with nasal polyps, and prurigo nodularis. JAK1/JAK3 inhibitors include tofacitinib and upadacitinib.
Reference: Neena Khanna Illustrated Synopsis of Dermatology & STD, 6th ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.